Dr. Usmani on DREAMM Trials in Multiple Myeloma

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the DREAMM-1 and DREAMM-2 trials in multiple myeloma.

In the phase I DREAM-1 trial, patients with relapsed/refractory multiple myeloma received the anti-BCMA antibody-drug conjugate, belantamab mafodotin (GSK2857916). In part 1 of the trial, the recommended phase II dose was determined to be 3.4 mg/kg administered as a 1-hour infusion once every 3 weeks for up to 16 cycles. Notably, responses were reported among patients who were refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

Subsequently, the randomized phase II DREAMM-2 trial was launched. In the trial, 196 patients with relapsed/refractory myeloma were randomized to receive 1 of two doses of belantamab mafodotin. In August 2019, belantamab mafodotin was reported to have met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the trial.